As the mutation distribution in TP53 is highly heterogenous and the length of the TP53 locus is shorter than the limit of the genomic fragment in the CRISPR/Cas technique, replacing the entire TP53 locus would increase the applicability of the CRISPR/Cas therapeutic system for MDS [89]. Here, TP53 is linked to myelodysplastic syndrome.